

la neumonía como de la infección por catéter, siendo una especie emergente. Se ha informado cada vez más que causa infecciones potencialmente mortales e incluso brotes en humanos^{3,4}.

Los factores de riesgo predisponentes a infección son el ingreso en unidad de cuidados intensivos, hospitalización prolongada, uso de inmunosupresores, presencia de dispositivos invasivos, enfermedades crónicas y el uso previo de antimicrobianos⁵.

En nuestro caso, podría tratarse de una bacteriemia relacionada con la asistencia sanitaria quizá en el contexto de su ingreso hospitalario reciente.

El género suele presentar resistencia a múltiples antibióticos, tanto por la formación de biopelículas^{3,6} como por la expresión de betalactamasas cromosómicas en el espacio periplásmico, concretamente una serino-betalactamasa de espectro extendido clase A de Ambler que le confiere resistencia a β -lactámicos y metalobetalactamasas clase B que hidrolizan carbapenémicos^{7–9}.

Como conclusión, destacamos que *E. anophelis* es un patógeno que debe ser vigilado por su implicación como causa de infecciones nosocomiales^{9,10} y por su resistencia a múltiples antibióticos.

Bibliografía

1. Lin JN, Lai CH, Yang CH, Huang YH. *Elizabethkingia* Infections in Humans: From Genomics to Clinics. *Microorganisms*. 2019;7:295. <http://dx.doi.org/10.3390/microorganisms7090295>.
2. Munson E, Carroll KC. Update on Accepted Novel Bacterial Isolates Derived from Human Clinical Specimens and Taxonomic Revisions Published in 2020 and 2021. *J Clin Microbiol*. 2023;61. <http://dx.doi.org/10.1128/jcm.00282-22>, e0028222.
3. Hu S, Xu H, Meng X, Bai X, Xu J, Ji J, et al. Population genomics of emerging *Elizabethkingia anophelis* pathogens reveals potential outbreak and rapid global dissemination. *Emerg Microbes Infect*. 2022;11:2590–9. <http://dx.doi.org/10.1080/22221751.2022.2132880>.
4. Comba IY, Schuetz AN, Misra A, Friedman DZP, Stevens R, Patel R, et al. Antimicrobial Susceptibility of *Elizabethkingia* Species: Report from a Reference Laboratory. *J Clin Microbiol*. 2022;60:e0254121. <http://dx.doi.org/10.1128/jcm.02541-21>.

5. Hu S, Lv Y, Xu H, 1 Zheng B, Xiao Y. Biofilm formation and antibiotic sensitivity in *Elizabethkingia anophelis*. *Front Cell Infect Microbiol*. 2022;12:953780.
6. Lau SK, Chow W-N, Foo C-H, Curreem SOT, Lo GCS, Teng JLL, et al. *Elizabethkingia anophelis* bacteremia is associated with clinically significant infections and high mortality. *Sci Rep*. 2016;6:26045. <http://dx.doi.org/10.1038/srep26045>.
7. Liuy K-M, Chang H-L, Hsu M-H, Lin Y-Z, Chen Y-T. Complete Genome Sequencing of *Elizabethkingia* sp. Strain 2-6. *Microbiol Resour Announc*. 2019;8. <http://dx.doi.org/10.1128/MRA.00805-19>, e00805-19.
8. Yasmin M, Rojas LJ, Marshall SH, Hujer AM, Cmolik A, Marshall, et al. Characterization of a Novel Pathogen in Immunocompromised Patients: *Elizabethkingia anophelis*—Exploring the Scope of Resistance to Contemporary Antimicrobial Agents and β -lactamase Inhibitors. *Open Forum Infect Dis*. 2023;10:1. <http://dx.doi.org/10.1093/ofid/ofad014>.
9. Brandariz Núñez D, Rodríguez Pedreira P, Hernández Corredoira V, Puig Forcada J, Gurri Hernand FJ, Boix Boix AS. Septic shock secondary to *Elizabethkingia meningoseptica*: A case report [Article in Spanish]. *Rev Esp Quimioter*. 2019;32:390–2.
10. Mensa J, Soriano A, López-Suñé E, Llinares P, Barberán J, Poliakova Y. 33.ª edición. Abril 2023. P. 1106. Editorial ANTARES. ISBN 978848825322.

Lourdes Balderas Fernández^{a,*}, Yolanda García Collado^a y Andrea Prolo Acosta^{b,c}

^a Unidad de Gestión Clínica Microbiología Clínica, Hospital Clínico Virgen de la Victoria, Málaga, España

^b Unidad de Gestión Clínica Enfermedades Infecciosas, Hospital Clínico Virgen de la Victoria, Málaga, España

^c Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA-Plataforma BIONAD), Málaga, España

* Autor para correspondencia.

Correo electrónico: lourdesbalferr@gmail.com (L. Balderas Fernández).

<https://doi.org/10.1016/j.eimc.2024.03.015>

0213-005X/ © 2024 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Tubercular longitudinally extensive transverse myelitis: An unmissable zebra grazing the Indian medical field



Mielitis transversa tuberculosa de gran extensión longitudinal: una cebra imposible de ignorar pastando en el campo médico de la India

Longitudinally extensive transverse myelitis (LETM) is characterized by the involvement of the spinal cord spanning three or more vertebral segments and appearing as hyperintense lesions on T2 weighted-imaging magnetic resonance imaging (MRI).^{1–5} The most well-known cause of LETM is primarily neuromyelitis optica spectrum disorders and, recently, the novel severe acute respiratory syndrome coronavirus infection.^{1–3}

We herein present a rare case of LETM where a search for the etiology revealed a previously undiagnosed pulmonary tuberculosis.

A 17-year-old male from suburban India was admitted to the emergency department presenting with two weeks of back pain, numbness, and tingling in both lower limbs, accompanied by increased urinary frequency. He complained of headaches and low-grade fever for the past two months and had recently developed a productive cough. His personal history was significant for smoking 3–4 beedis per day.

A neurological exam revealed spastic paraplegia and patchy loss of pain, touch, and temperature sensation below the D4 spinal level. Joint and vibration senses were lost. The patient had difficulty in performing the finger nose test and dysidiadochokinesia. The remaining of the neurological examination was normal.

A diagnosis of non-compressive myelopathy with cerebellar dysfunction was made. Routine laboratory investigations were normal findings except for mild anemia. Digital chest X-ray revealed cavities and infiltrates throughout both lungs, accompanied by enlargement of the hilar lymph nodes (Fig. 1). The sputum sample tested for acid-fast bacilli was negative. However, a subsequent cartridge-based nucleic acid amplification test detected *Mycobacterium tuberculosis* in the sputum sample. The cerebrospinal fluid (CSF) study results were as follows: cell count was 4 cells per mm³, the protein level was 60 mg/dl, the glucose level was 74 mg/dl, the adenosine deaminase level was 1.3 U/L, and the acid-fast bacilli Ziehl–Neelsen stain was negative. In addition, the CSF analysis was negative for anti-myelin oligodendrocyte glycoprotein and anti-aquaporin 4 antibodies, as well as herpes simplex virus types 1 and 2. Anti-nuclear antibody (ANA), ANA profile, and autoimmune vasculitis profile were negative; serum C3 and C4 were slightly elevated, with 297 mg/dl and 48 mg/dl, respectively. HIV, HBsAg, anti-HCV, and VDRL were negative. A contrast-enhanced MRI of the brain and spine revealed non-enhancing altered intensity from the D4–D5 level to the distal end of the spinal cord (Fig. 2A). In addi-



Fig. 1. Digital posteroanterior chest X-ray revealing cavities and infiltrates throughout both lungs, accompanied by enlargement of the hilar lymph nodes.




Fig. 2. Mid-sagittal T2-weighted magnetic resonance imaging (MRI) demonstrating changes in signal intensity from the D4–D5 vertebral level to the terminal portion of the spinal cord, indicated by arrows (A). Axial T1-weighted MRI with gadolinium contrast highlights a lesion with altered signal intensity, surrounding edema, and ring enhancement suggestive of a granuloma in the left cerebellar hemisphere, marked by arrow (B).

tion, an altered intensity, perilesional lesion with edema and ring enhancement (granuloma) in the left cerebellar hemisphere was observed (Fig. 2B).

The patient received a three-day regimen of intravenous methylprednisolone at 1 gram daily, which led to significant clinical improvement. Concurrently, IV dexamethasone at a dosage of 0.4 mg/kg/day was administered throughout the hospitalization period. Upon discharge, the treatment plan included an oral prednisolone regimen starting at 40 mg daily, gradually tapered over the next two months. Additionally, the patient was initiated on anti-tubercular therapy in accordance with the guidelines outlined by the National Tuberculosis Elimination Programme (NTEP). Initially, considering the patient's weight of 48 kg, a regimen consisting of three tablets of a fixed drug combination containing isoniazid (75 mg), rifampicin (150 mg), ethambutol (400 mg), and pyrazinamide (275 mg) was administered daily. As the patient's weight surpassed 50 kg, the dosage was adjusted to four tablets of the same fixed drug combination daily, maintained for two months, constituting the intensive phase. This was followed by a continuation phase las-

ting 16 months, during which four tablets each of isoniazid (75 mg), rifampicin (150 mg), and ethambutol (400 mg) were administered daily.

At the six-month follow-up, the patient demonstrated no notable neurological deficits. Imaging, including an MRI of the brain and spine, showed no abnormalities, and a chest X-ray indicated significant resolution of the lesions previously observed.

Tubercular LETM is an uncommon diagnosis, and all individuals who present with symptoms indicative of transverse myelitis should undergo thorough investigations for a potential underlying tubercular infection, especially in countries like India, where tuberculosis is endemic.⁴

The precise mechanisms by which *Mycobacterium tuberculosis* leads to LETM are not fully elucidated. It is hypothesized that tuberculous myelitis results from an immune-mediated reaction directed against the antigens from the *Mycobacterium* cell wall, which subsequently causes inflammatory demyelination of the spinal cord.⁴

Neuroimaging played a critical role in the diagnosis of this case, revealing extensive involvement of the spinal cord. Furthermore, a chest X-ray demonstrated typical features of pulmonary tuberculosis. The analysis of CSF showed elevated protein levels, indicative of inflammation or infection affecting the central nervous system. Additionally, the diagnosis was confirmed by a positive result for *Mycobacterium tuberculosis* in the sputum sample. These features underscore the complexity of diagnosing tubercular myelitis, highlighting the necessity for a comprehensive approach that integrates clinical, radiological, and laboratory findings to achieve accurate diagnosis and effective treatment.⁴

It is crucial to emphasize that obtaining bacterial confirmation of tuberculosis can be challenging due to the disease's paucibacillary nature, particularly in cases of extrapulmonary tuberculosis.⁴ Therefore, a high index of clinical suspicion, supported by corroborative evidence from neuroimaging and laboratory investigations, should suffice to establish a diagnosis of tuberculosis and initiate treatment.⁴

Authors' contributions

All authors contributed significantly to the creation of this manuscript; each fulfilled the criterion established by the ICMJE.

Ethical statement

Written informed consent was obtained from the patient participating in the study (consent for research). We also confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Funding

Nil.

Conflict of interest

Dr. Ila Singh (ilasingh188@gmail.com) reports no relevant disclosures.

Dr. Niranjana Panda (panda.niranjana1992@gmail.com) reports no relevant disclosures.

Dr. Ritwik Ghosh (ritwikmed2014@gmail.com) reports no relevant disclosures.

Dr. Julián Benito-León (jbenitol67@gmail.com) reports no relevant disclosures.

Acknowledgments

J. Benito-León is supported by the National Institutes of Health, Bethesda, MD, USA (NINDS #R01 NS39422), the Recovery, Transformation and Resilience Plan of the Spanish Ministry of Science and Innovation (grant TED2021-130174B-C33, NETremor), and the Spanish Ministry of Science and Innovation (grant PID2022-138585OB-C33, Resonate).

Bibliografía

1. Ghosh MdR, Roy D, León-Ruiz M, Das S, Dubey S, Benito-León J. Seropositive neuromyelitis optica in a case of undiagnosed ankylosing spondylitis: a neuro-rheumatological conundrum. *Qatar Med J*. 2022;2022:29, <http://dx.doi.org/10.5339/qmj.2022.29>. PMID: 35864917; PMCID: PMC9272764.
2. Ghosh R, De K, Roy D, Mandal A, Biswas S, Biswas S, et al. A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection. *J Neuroimmunol*. 2020;350:577439, <http://dx.doi.org/10.1016/j.jneuroim.2020.577439>. Epub ahead of print. PMID: 33333471; PMCID: PMC7657006.
3. Mondal R, Deb S, Shome G, Ganguly U, Lahiri D, Benito-León J. COVID-19 and emerging spinal cord complications: a systematic review. *Mult Scler Relat Disord*. 2021;51:102917, <http://dx.doi.org/10.1016/j.msard.2021.102917>. Epub 2021 Mar 21; PMID: 33845350; PMCID: PMC7981271.
4. Anand KA, Bhowmik KK, Sarkar A, Ghosh R, Mandal A, Swaika B, et al. Tubercular longitudinally extensive transverse myelitis (LETM): an enigma for primary care physicians. *J Family Med Prim Care*. 2021;10:1057–60, <http://dx.doi.org/10.4103/jfmpc.jfmpc.2101.20>. Epub 2021 Feb 27; PMID: 34041124; PMCID: PMC8138341.
5. Ghosh R, Mandal A, León-Ruiz M, Roy D, Das S, Dubey S, et al. Rare neurological and neuropsychiatric manifestations of scrub typhus: a case series of 10 cases. *Neurologia (Engl Ed)*. 2022, <http://dx.doi.org/10.1016/j.nrleng.2022.07.001>. S2173-5808(22)00081-5. Epub ahead of print. PMID: 35907627.

Ila Singh^a, Niranjan Panda^a, Ritwik Ghosh^a,
Julián Benito-León^{b,c,d,e,*}

^a *Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, India*

^b *Department of Neurology, University Hospital “12 de Octubre”, Madrid, Spain*

^c *Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain*

^d *Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain*

^e *Department of Medicine, Faculty of Medicine, Complutense University, Madrid, Spain*

* Corresponding author.

E-mail address: jbenitol67@gmail.com (J. Benito-León).

<https://doi.org/10.1016/j.eimc.2024.04.002>

0213-005X/ © 2024 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.